




Handwritten text, possibly a date or initials, in the top right corner.

July 2, 1990  
SJB-90-143



Professor Joshua Lederberg  
Suite 400, Founder's Hall  
The Rockefeller University 1230 York Avenue  
New York, New York 10021-6399

Dear Josh:

Thanks for your recent note regarding the exchange of letters between those "pro" and "con" biological asymmetric synthesis. Perhaps the most revealing aspect of the exchange of letters is that neither party used the right examples! It reflects, at best, ignorance of industrial reality (e.g. an important industrial product arising from biological asymmetric synthesis is chiral  $\beta$ -hydroxy isobutyric acid used in Captopril manufacture - the process is impressively carried out by the Japanese firm Kaneka - indeed, I wonder if our Far Eastern friends are not looking on in amazement at this exchange of letters!).

On the home front, we are scaling-up our chiral amine technology (enantiospecific aminotransferase, broad patent to issue soon) and will shortly submit a bid for multiple metric ton sales. If all goes according to plan, it will be a major step for Celgene.

In case you hadn't heard by now, we have a new CEO - Jack Ufheil, formerly of Mallinckrodt (news release enclosed). Lou has moved upstairs.

Thanks for keeping on thinking of us - I'll keep you informed!

Sincerely,

Handwritten signature of Dr. Sol J. Barer, with a checkmark to the left.

Dr. Sol J. Barer  
Vice President, Technology

Enclosure

mjn